1. Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
Maryam Sattari, MD, MS, Jane A. Cauley, DrPH, Cynthia Garvan, PhD, Karen C. Johnson, MD, MPH, Michael J. LaMonte, PhD, MPH, Wenjun Li, PhD, Marian Limacher, MD, Todd Manini, PhD, Gloria E. Sarto, MD, PhD, Shannon D. Sullivan, MD, PhD, Jean Wactawski- Wende, PhD, Rebecca J. Beyth, MD, MSc 
The American Journal of Medicine 
Volume 130, Issue 8, Pages (August 2017)
DOI: /j.amjmed
Copyright © 2017 Elsevier Inc. Terms and Conditions

2. Figure 1
STROBE Flow Diagram of Analytic Cohort (n = 17,803) with inclusion and exclusion criteria. CAD = Calcium/Vitamin D supplementation Trial; CT = clinical trial; DM = Dietary Modification Trial; HT = hormone therapy; SERMs = selective estrogen receptor modulators. *Participants in the final analytic cohort with medication data available after their fracture or osteoporosis diagnosis.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2017 Elsevier Inc. Terms and Conditions

3. Figure 2
Odds ratios and 95% confidence intervals for appropriate osteoporosis treatment. Odds ratios have been adjusted for the following variables in the model: age, income, optimism, negative emotional construct, activities of daily living, alcohol intake, energy expenditures per week, vitamin D intake, calcium intake, education, number of medications, osteoporosis diagnosis by fracture site, race, region, smoking status, general health, insurance status, number of falls, health care provider, disability, marital status, mammograms, Pap smears, main job, depression, body mass index, self-rate health status, primary care provider visit in the past year, hormone use, number of medications, history of arthritis, cardiovascular disease, hypertension, hip replacement, and other joint replacement. HRT = hormone therapy.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2017 Elsevier Inc. Terms and Conditions